Diana Langworthy: New Episode – Solving the DOAC vs. Warfarin Mystery in Cirrhosis
Diana Langworthy, Associate Professor at University of Minnesota College of Pharmacy, shared a post on LinkedIn:
“New episode going live tomorrow, Tuesday June 30th, on What’s It Worth?
S4E7 – The Cirrhosis Paradox: Solving the DOAC vs. Warfarin Mystery in Liver Disease
Join me and my co-hosts, Dr. Erin E Pauling, (ambulatory care and cardiology specialist from Binghamton University) and recent U of MN grad, Dr. Caleb Nelson-Lange.
In this episode, we dig into a systematic review and meta-analysis comparing DOACs vs. warfarin in patients with atrial fibrillation and liver disease, including cirrhosis.
We talk through:
Why anticoagulation decisions in liver disease are so nuanced
What the evidence suggests about DOAC safety and effectiveness
How to think about agent selection, especially apixaban vs. rivaroxaban
Why observational data can be helpful, but still leaves important clinical gaps
And with this episode, there is a patient-facing companion episode:
S4E7.5 – AFib, Blood Thinners, and Liver Disease: Questions to Ask Your Doctor
This short What’s It Worth? For Everyone episode is designed for patients and families navigating AFib, blood thinners, liver disease, and cirrhosis.
It explains the topic in plain language and ends with practical questions patients can bring to their healthcare team.
For healthcare professionals: listen to the full episode for the evidence deep dive, and consider sharing the companion episode with patients or caregivers who want a clearer starting point for the conversation.”
Stay updated with Hemostasis Today.
-
Oct 2, 2026, 14:30Sadashiva Pai: The Molecular Gateway for Sphingosine-1-Phosphate Release
-
Oct 2, 2026, 14:17Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
-
Oct 2, 2026, 14:12Monitoring Iron Deficiency in Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Oct 2, 2026, 14:06Giang Tran: Residual Internal Carotid Artery Aneurysm After Flow-Diverter Stenting
-
Oct 2, 2026, 14:05Shadiah Nassanga: The Economic Impact of Sickle Cell Disease
-
Oct 2, 2026, 13:56Mapping the Care Gaps for Hemophilia and Sickle Cell Disease in Ghana – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Oct 2, 2026, 13:50Arnav Garcha: New Insights Into Platelet Transport in Arterial Flow
-
Oct 2, 2026, 13:49Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
-
Oct 2, 2026, 13:43Ronald Mahomane: Bangladesh Moves Toward Sustainable Hemophilia Treatment Access